Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

FDA approves new dosage strength of Lodine XL

Feb. 10, 1998

Positive preclinical results reported for IPL-423

Feb. 10, 1998

Several related series of MMP inhibitors claimed by Bayer

Feb. 9, 1998

Yeda patents IFN-alpha/beta receptor-neutralizing antibodies

Feb. 3, 1998

Phase III results reported for Prosorba

Jan. 30, 1998

ADIR prepares MMP inhibitors for arthritis, cancer, atherosclerosis

Jan. 27, 1998

Boston Life Sciences to seek U.S. approval for Therafectin

Jan. 23, 1998

Inhibitors of prostaglandin biosynthesis prepared at Abbott

Jan. 23, 1998

Connetics amends payment terms, sells Canadian rights to Ridaura

Jan. 22, 1998

Inhibitors of COX-1/COX-2 from Roche

Jan. 22, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...